Siegmund, Daniela
Wajant, Harald http://orcid.org/0000-0002-2005-3949
Article History
Accepted: 5 July 2023
First Online: 4 August 2023
Competing interests
: H.W. declares that he received consultancy fees from Dualyx NV regarding the targeting of T<sub>reg</sub> cells via TNF receptor 2 (TNFR2). D.S. declares no competing interests. The University of Würzburg has filed patent applications for “Novel TNFR2 binding molecules” and “Tumour necrosis factor (TNF) receptor superfamily (TNFRSF) receptor-activating antibody fusion proteins with FcγR-independent agonistic activity (TRAAFFIA)”, with H.W. as one of the inventors.